Jazz Pharmaceuticals JAZZ

HealthcareMarket cap $7B1 connection

Jazz Pharmaceuticals makes Xyrem/Lumryz for narcolepsy (a sleeping disorder affecting 200,000+ Americans), Epidiolex (the first FDA-approved cannabis-derived drug, for epilepsy), and oncology drugs. Its specialty pharmaceutical model targets underserved diseases where pricing power is high and generics are limited.

Explore Jazz Pharmaceuticals on the interactive map Relationship timeline Find a path to another company

Partners 1

Strategic partnerships, joint products and alliances

Johnson & JohnsonHealthcare · $380BJazz narcolepsy drug competing with J&J pipeline

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Jazz Pharmaceuticals's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=JAZZ" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Jazz Pharmaceuticals on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.